HTG Molecular Diagnostics (HTGM) Stock Price, News & Analysis

HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) posted its quarterly earnings results on Wednesday, November, 10th. The medical research company reported ($0.60) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.60). The medical research company had revenue of $2.52 million for the quarter, compared to the consensus estimate of $2.90 million. HTG Molecular Diagnostics had a positive trailing twelve-month return on equity of 45.52% and a negative net margin of 324.25%. During the same period in the prior year, the business earned ($1.05) EPS.

11 employees have rated HTG Molecular Diagnostics Chief Executive Officer Tim (TJ) Johnson on Glassdoor.com. Tim (TJ) Johnson has an approval rating of 47% among the company's employees. This puts Tim (TJ) Johnson in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other HTG Molecular Diagnostics investors own include Idera Pharmaceuticals (IDRA), Biocept (BIOC), Rigel Pharmaceuticals (RIGL), Heat Biologics (HTBX), MEI Pharma (MEIP), Zosano Pharma (ZSAN), Verastem (VSTM), Aurinia Pharmaceuticals (AUPH), Dynavax Technologies (DVAX) and Gilead Sciences (GILD).

HTG Molecular Diagnostics (HTGM) raised $50 million in an IPO on Wednesday, May 6th 2015. The company issued 3,600,000 shares at $13.00-$15.00 per share. Leerink Partners served as the underwriter for the IPO and Canaccord Genuity and JMP Securities were co-managers.